Cargando…
Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report
RATIONALE: For advanced non-small-cell lung cancer (NSCLC), targeted therapy and chemoradiotherapy are recommended as the first-line treatment. For patients with a performance status (PS) score over 2 and without gene mutation, however, only supportive treatment is provided and survival time is extr...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344168/ https://www.ncbi.nlm.nih.gov/pubmed/30608421 http://dx.doi.org/10.1097/MD.0000000000013924 |